Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DerG-PG275Cit
- Development stage
- Preclinical
- Lead developer
- CEL-SCI
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
DerG-PG275Cit is a preclinical therapeutic vaccine candidate developed by CEL-SCI for the treatment of rheumatoid arthritis. It is a fusion protein and part of the LEAPS (Ligand Epitope Antigen Presentation System) platform, designed to modulate immune responses by targeting CD4 T cells. The vaccine incorporates a citrullinated epitope from cartilage proteoglycan (PG), which is relevant in autoimmune pathogenesis. In animal models of rheumatoid arthritis, DerG-PG275Cit has demonstrated immunomodulatory effects—specifically upregulating regulatory T cells and anti-inflammatory cytokines such as IL-4 and IL-10—without eliciting significant antibody responses. Its mechanism involves shifting pro-inflammatory Th1/Th17 responses toward an anti-inflammatory/regulatory profile via CD4 modulation[1][2][6][7][8]. The drug remains in preclinical development.
- Other names
- DerGPG275CitDerGPG-275CitDerGPG 275CitLEAPS vaccine (DerG-PG275Cit)
02
Targets
CD4 (T lymphocyte surface antigen)
Beyond the preview
Go deeper on DerG-PG275Cit.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DerG-PG275Cit.